Editas Medicine Nasdaq Edit expects to dose the first patients this year in a Phase I II study of its lead gene-editing candidate, Edit-401, as the company focuses its development strategy on in vivo CRISPR therapies. Sp
Why Is Editas Medicine, Inc. (EDIT) Stock Down Today?
Updated Nov 16, 2026 8:00 PM ET · Prev Close $2.17
Primary Move Catalyst & Conviction
65% Signal ConvictionBiotechnology & Biological Products sector moving together
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Market & Sector Relative Strength
EDIT lagging the S&P 500 by -10.32%Options Flow & Execution Desk
Bullish Flow · P/C 0.63Unlock 2 Strike-Verified Options Setups for EDIT
Our options desk modeled ATM Call Rebound / Continuation, ATM Put Downside Positioning structures for the Dec 18 expiration cycle, plus live unusual contract strike sweeps and full factor sub-scores.
Recent EDIT Catalyst Headlines
Verified WireEditas EDIT delivered earnings and revenue surprises of 28.57 and 498.10 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
EDIT on Monday reported a loss of 23.On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 15 cents.
Company received HREC approval to initiate Phase 1 2 Strive study of Edit-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating 90 percent LDL-C reductio
1–3 Day Expected Range & Key Level
35% Follow-ThroughWatch for breakdown below $1.91
Technical Regime (EDIT)
BEARISH MA TREND1-Year Historical Move Analogs
70 EventsSessions in the past year where EDIT moved >3.0% down:
Retail & Crowd Sentiment
Very BullishStockTwits shows bullish sentiment towards $EDIT, with one user expecting a rebound after hours and a potential upward trend come Monday.
About Editas Medicine, Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short pali...
Get Instant EDIT Catalyst Alerts
Receive an email alert when EDIT triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversEDIT Session & Catalyst FAQ
Why is EDIT stock down today?
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Is EDIT stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.58x relative volume (low participation). Our multi-factor model currently rates EDIT as HOLD. Review full valuation, quality, and timing signals on the EDIT Buy or Sell Decision Brief →
What is EDIT's intrinsic value and expected trading range?
At $1.91, EDIT's modeled 1-to-3 session range is $1.85 – $1.94, with a key inflection level at $1.81 (support). Compare current price against multi-year cash flow projections in the EDIT Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for EDIT?
RSI at 35.1 reflects soft below-midline momentum. EDIT trades at $1.91 relative to its 20-day SMA ($2.52) and 50-day SMA ($2.61), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.